List of Excipients in Branded Drug CIPROFLOXACIN AND DEXAMETHASONE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sandoz Inc	CIPROFLOXACIN AND DEXAMETHASONE	ciprofloxacin and dexamethasone	0781-6186	ACETIC ACID
Sandoz Inc	CIPROFLOXACIN AND DEXAMETHASONE	ciprofloxacin and dexamethasone	0781-6186	BENZALKONIUM CHLORIDE
Sandoz Inc	CIPROFLOXACIN AND DEXAMETHASONE	ciprofloxacin and dexamethasone	0781-6186	BORIC ACID

Generic Drugs Containing CIPROFLOXACIN AND DEXAMETHASONE

Company	Ingredient	NDC	Excipient
Upsher-Smith Laboratories LLC	ciprofloxacin hydrochloride and dexamethasone	0832-1430	ACETIC ACID
Upsher-Smith Laboratories LLC	ciprofloxacin hydrochloride and dexamethasone	0832-1430	BENZALKONIUM CHLORIDE
Upsher-Smith Laboratories LLC	ciprofloxacin hydrochloride and dexamethasone	0832-1430	BORIC ACID

What are the Most Frequently-Used Excipients in CIPROFLOXACIN AND DEXAMETHASONE?

# Of NDCs	Excipient
16	ACETIC ACID
16	BENZALKONIUM CHLORIDE
16	BORIC ACID

Ciprofloxacin and Dexamethasone Excipient Strategy and Commercial Opportunities

Last updated: October 9, 2026

Ciprofloxacin/dexamethasone is a mature prescription combination used primarily as an otic suspension for bacterial ear infections with inflammation. The reference product, Ciprodex, combines ciprofloxacin 0.3% with dexamethasone 0.1% and uses a sterile aqueous suspension containing hydroxyethyl cellulose, benzalkonium chloride, acetate salts, boric acid, sodium chloride, and water for injection [1].

The commercial opportunity is no longer based on basic active-ingredient exclusivity. It is concentrated in differentiated excipient systems, preservative-free delivery, pediatric usability, container-device performance, manufacturing efficiency, and branded or private-label generic distribution.

What is ciprofloxacin/dexamethasone and how is it used?

Ciprofloxacin/dexamethasone is a topical fluoroquinolone-corticosteroid combination. The otic product is indicated for:

• Acute otitis externa in adults and pediatric patients
• Acute otitis media in pediatric patients with tympanostomy tubes

The approved Ciprodex dosage is four drops into the affected ear twice daily for seven days. The product is a sterile suspension rather than a clear solution because dexamethasone has limited aqueous solubility at the required concentration [1].

Attribute	Reference product profile
Brand	Ciprodex
Active ingredients	Ciprofloxacin 0.3%; dexamethasone 0.1%
Dosage form	Sterile otic suspension
Route	Topical ear administration
Main indications	Otitis externa; otitis media with tympanostomy tubes
Typical course	Seven days
Preservative	Benzalkonium chloride
Key viscosity agent	Hydroxyethyl cellulose
Regulatory pathway	New drug application followed by abbreviated new drug applications
Product category	Small-molecule combination drug
Biosimilar exposure	None

The combination addresses two treatment objectives: ciprofloxacin suppresses susceptible bacterial infection, while dexamethasone reduces local inflammation, pain, edema, and discharge.

What excipients are used in Ciprodex?

The Ciprodex formulation contains the following inactive ingredients:

Excipient	Functional role
Hydroxyethyl cellulose	Suspending and viscosity-building agent
Benzalkonium chloride	Antimicrobial preservative
Acetic acid	pH adjustment and buffering
Sodium acetate	Buffer component
Boric acid	Tonicity and formulation adjustment
Sodium chloride	Tonicity adjustment
Water for injection	Sterile vehicle

The formulation is designed to keep ciprofloxacin and dexamethasone particles uniformly dispersed during storage and administration. The patient must shake the bottle before use because the product is a suspension [1].

The excipient system has four technical priorities:

1. Maintain physical stability during shelf life.
2. Deliver a consistent dose after shaking.
3. Preserve sterility after repeated opening.
4. Avoid irritation in inflamed or surgically treated ear tissue.

An alternative formulation must preserve these performance characteristics while avoiding changes that could trigger a more burdensome regulatory comparison.

How does the suspension excipient system affect product performance?

Hydroxyethyl cellulose

Hydroxyethyl cellulose increases viscosity and slows particle settling. It also improves residence time in the external auditory canal and may reduce runoff after administration.

The main development risks are:

• Excessive viscosity that makes the product difficult to dispense
• Incomplete redispersion after storage
• Dose nonuniformity between early and late doses
• Interaction with preservatives or container surfaces
• Increased filling and mixing complexity

A lower-viscosity product may improve administration but can settle rapidly. A higher-viscosity product may improve retention but create dosing variability if the patient does not shake the bottle adequately.

Benzalkonium chloride

Benzalkonium chloride is widely used in ophthalmic and otic products, but it can cause irritation or epithelial toxicity at sufficient exposure. This creates a commercial opening for preservative-free products, particularly for:

• Infants and young children
• Repeated or recurrent treatment
• Patients with sensitive skin or chronic ear disease
• Postoperative patients
• Patients who receive multiple topical products

A preservative-free version would need a single-dose container, a validated sterile multidose system, or another packaging configuration that prevents microbial contamination during use.

Buffering and tonicity agents

Acetate, boric acid, and sodium chloride support pH and osmolarity control. The ear is less sensitive to ophthalmic-level tonicity requirements than the eye, but highly acidic, alkaline, or hypertonic formulations may increase discomfort in damaged tissue.

A reformulation program should assess:

• pH tolerance in inflamed ear tissue
• Short-term tolerability after tympanostomy
• Chemical stability of ciprofloxacin
• Dexamethasone degradation products
• Preservative efficacy
• Compatibility with silicone, elastomer, and plastic packaging

Water for injection and sterile processing

The aqueous vehicle requires sterile manufacturing and microbial control. The product does not need refrigeration under the labeled storage conditions, which simplifies distribution and supports pharmacy, hospital, pediatric, and international markets.

What formulation patents protect ciprofloxacin/dexamethasone?

The original Ciprodex patent estate focused on the combination and suspension formulation rather than on new molecular entities. Ciprofloxacin and dexamethasone are both long-established active ingredients with expired or commercially exhausted basic composition-of-matter protection.

Historically relevant U.S. patent protection associated with Ciprodex included formulation and combination claims, including U.S. Patent No. 5,980,882, which was listed in connection with the product’s earlier commercial protection. The principal commercial exclusivity period has expired, and the market now includes generic ciprofloxacin/dexamethasone otic suspensions.

Protection category	Current commercial significance
Ciprofloxacin composition of matter	Expired
Dexamethasone composition of matter	Expired
Original combination formulation	Historical protection; no longer a durable barrier
Suspension technology	Potentially protectable if materially differentiated
Preservative-free presentation	Potential formulation and packaging opportunity
Device-assisted delivery	Potentially protectable through device and use claims
Manufacturing process	Potential trade-secret and process-patent value
Method of use	Limited value for the approved mature indications
Pediatric indication	No meaningful current exclusivity barrier

The strongest new patent opportunities are narrow. They may cover particle size, crystal form, rheology, preservative-free sterile packaging, container closure systems, dose delivery, or manufacturing controls. Such patents would not automatically prevent all generic competition.

When did ciprofloxacin/dexamethasone lose exclusivity?

Ciprodex was approved by the FDA in 2003. Its market exclusivity period has ended, and generic versions have been approved through the ANDA pathway.

The product’s competitive timeline is:

Event	Approximate timing
Ciprodex FDA approval	2003
New drug exclusivity period	Expired
Pediatric exclusivity	Expired
Original formulation patent protection	Expired
Generic ANDA competition	Established
Current market status	Mature, multi-source prescription market

The product is therefore a genericized combination rather than a protected growth asset. New commercial value must come from formulation, packaging, channel access, manufacturing cost, or clinical differentiation.

What is the Orange Book status of ciprofloxacin/dexamethasone?

Ciprodex is listed in the FDA Orange Book as a prescription drug product associated with NDA 021537. The relevant dosage form is an otic suspension containing ciprofloxacin and dexamethasone [2].

The Orange Book’s current commercial importance is limited because:

• The active ingredients are old small molecules.
• Original exclusivity has expired.
• Generic ANDA approvals are available.
• Any remaining listed patent claims must be evaluated individually for expiration and scope.
• Formulation changes may require a new NDA, a suitability petition, or another FDA pathway depending on the proposed product.

Generic applicants may certify against listed patents under Paragraph III or Paragraph IV. Paragraph IV certifications historically create litigation risk, but they do not create a durable barrier when the patents are expired or commercially weak.

Which companies are challenging or competing with Ciprodex?

Competition comes primarily from generic manufacturers rather than biosimilar developers. Known market participants have included large generic companies and specialty pharmaceutical suppliers marketing ciprofloxacin/dexamethasone otic suspension under abbreviated applications.

The competitive structure includes:

Competitor type	Business model	Main advantage
Authorized generic	Same or highly similar product through an authorized channel	Physician and pharmacy familiarity
Conventional ANDA generic	Bioequivalent or therapeutically equivalent product	Lower acquisition cost
Private-label supplier	Contract manufacturing and distributor branding	Channel flexibility
Single-product specialty company	Focus on ENT and pediatric prescribing	Sales-force concentration
Reformulation developer	New excipient or packaging profile	Potential premium pricing
Compounded preparation	Pharmacy-specific preparation	Customization, but less scalable

There is no biosimilar pathway for this product because it is a small-molecule topical combination. The competitive risk is generic substitution, not biosimilar interchangeability.

What commercial opportunities exist for new excipient strategies?

1. Preservative-free single-dose packaging

A preservative-free product is the clearest formulation opportunity. Single-dose ampoules or unit-dose blow-fill-seal containers could eliminate benzalkonium chloride and target sensitive or pediatric patients.

Commercial advantages include:

• Reduced preservative-related irritation
• Clearer differentiation from standard generics
• Suitability for hospital and surgical channels
• Potential use in patients requiring repeated courses
• Premium pricing potential

The disadvantages are higher packaging cost, larger packaging volume, more complex distribution, and the need to manage waste.

2. Preservative-free multidose delivery

A multidose container with a sterile valve or antimicrobial closure could improve convenience while avoiding conventional preservatives. This approach is technically more difficult because the container must maintain sterility throughout repeated use.

Development requirements include:

• Microbial ingress testing
• Dose-delivery consistency
• Container-closure integrity
• Extractables and leachables assessment
• Priming and residual-volume studies
• Compatibility with suspension particles

A multidose system may offer a better commercial proposition than unit-dose packaging if the device cost remains controlled.

3. Improved suspension and redispersion

A product that redisperses rapidly with fewer shakes could address a practical use problem. The target claims would need to remain consistent with FDA requirements and avoid unsupported clinical assertions.

Potential formulation tools include:

• Alternative cellulose polymers
• Controlled particle-size distributions
• Wetting agents
• Suspending-agent combinations
• Surface modification of active particles
• Optimized milling and homogenization

The value is highest if the reformulation produces better dose uniformity, lower sedimentation, and easier administration without increasing irritation.

4. Reduced-drip and improved ear retention

A rheology system that increases residence time may reduce leakage from the ear canal. A moderate increase in viscosity can create a more patient-friendly product, but excessive viscosity can interfere with drop formation and dosing.

The commercial opportunity is strongest for pediatric products, where caregivers may have difficulty retaining drops in the ear.

5. Unit-dose pediatric presentations

Unit-dose packaging can address contamination concerns and simplify treatment in pediatric or institutional settings. The primary challenges are manufacturing cost and adherence to a seven-day treatment course.

A 14-dose package could align with twice-daily dosing for seven days. A smaller package could reduce waste but may increase pharmacy dispensing complexity.

6. Alternative container and delivery formats

Potential formats include:

• Low-force squeeze bottles
• Metered-dose pumps
• Dropper systems with improved dose control
• Single-use twist-off containers
• Tamper-evident pediatric packages
• Hospital-ready unit-dose trays

The delivery device may support patent protection where the active formulation itself cannot. Device claims should be separated from formulation claims to improve enforcement flexibility.

What manufacturing and intellectual-property barriers affect the product?

The main manufacturing barriers are technical rather than molecular. A commercial product must control:

• Active-particle size and morphology
• Uniform suspension concentration
• Sedimentation and redispersion
• Sterility assurance
• Preservative distribution
• Fill-volume accuracy
• Container closure integrity
• Extractables and leachables
• Stability after opening

Ciprofloxacin and dexamethasone have different physicochemical properties. A manufacturing process must prevent selective settling, agglomeration, and concentration gradients.

A differentiated manufacturer may build defensible know-how around:

• Milling conditions
• Order of ingredient addition
• Hydration of hydroxyethyl cellulose
• Homogenization energy
• Deaeration
• Aseptic filling
• In-process particle-size controls
• Device filling and priming

Trade secrets may be more valuable than patents for process parameters that are difficult to detect from the finished product.

What FDA regulatory pathways apply to reformulated products?

A conventional copy of the reference otic suspension can generally proceed through the ANDA pathway if it meets applicable requirements for sameness, quality, performance, and therapeutic equivalence.

A product with a new excipient system or delivery device may face a more complicated pathway. Key considerations include:

• Whether the product remains pharmaceutically equivalent
• Whether the excipient change affects local safety
• Whether the new device changes dose delivery
• Whether comparative performance testing is required
• Whether the product can rely on a reference listed drug
• Whether a new NDA is necessary

For otic products, in vitro characterization and local tolerability may be central because conventional systemic bioequivalence measurements are not always sufficient to establish equivalence for a suspension with a materially different formulation.

A preservative-free product may have the best strategic profile if it can remain within an ANDA framework while providing a meaningful market distinction. If the formulation or device creates major differences, the development program may require additional FDA interaction and clinical or comparative-performance work.

What generic launch risks exist?

Generic launch risk is high for an undifferentiated product. Ciprofloxacin/dexamethasone otic suspension is a mature market with established generic supply and limited molecular differentiation.

Key risks include:

Risk	Commercial effect
Price erosion	Limits margin for standard ANDA products
Pharmacy substitution	Reduces branded retention
Short treatment duration	Restricts annual units per patient
Low switching costs	Increases generic penetration
Supply interruptions	Can create temporary opportunities
Device complexity	Raises cost and regulatory burden
Preservative-free manufacturing	Increases unit cost
Limited prescriber differentiation	Makes premium pricing difficult

The most attractive launch strategy is a targeted product with a measurable benefit, such as preservative-free packaging, pediatric dosing convenience, or improved delivery reliability.

How does ciprofloxacin/dexamethasone compare with competing ear-drop products?

Product category	Antibacterial	Steroid	Typical positioning
Ciprofloxacin/dexamethasone	Ciprofloxacin	Dexamethasone	Broad antibacterial and anti-inflammatory treatment
Ofloxacin	Ofloxacin	No	Lower-cost antibacterial option
Ciprofloxacin/hydrocortisone	Ciprofloxacin	Hydrocortisone	Antibacterial and anti-inflammatory treatment
Neomycin/polymyxin B/hydrocortisone	Neomycin and polymyxin B	Hydrocortisone	Established, low-cost combination
Steroid-only otic products	No	Variable	Inflammation without antibacterial coverage

Ciprofloxacin/dexamethasone has advantages where clinicians want a fluoroquinolone with a potent corticosteroid and avoid aminoglycoside ototoxicity concerns in certain clinical settings. Its disadvantages are higher cost than some older combinations and the absence of meaningful composition-of-matter exclusivity.

What revenue exposure and licensing opportunities exist?

Public revenue exposure for Ciprodex is difficult to isolate because product sales may be reported within broader ophthalmic, otic, or generic portfolios. The commercial model is typically driven by prescription volume, payer reimbursement, pharmacy substitution, and hospital contracts rather than long-duration chronic use.

Potential licensing opportunities include:

• Preservative-free otic formulations
• Sterile unit-dose manufacturing
• Metered-dose otic delivery devices
• Regional rights for emerging markets
• Private-label supply agreements
• Contract manufacturing for hospital systems
• Co-development with ENT-focused companies
• Licensing of suspension or particle-engineering technology

Licensing value depends more on regulatory status, manufacturing readiness, and channel access than on the underlying active ingredients.

How strong is the patent estate for ciprofloxacin/dexamethasone?

The legacy patent estate is weak as a barrier to standard generic entry. The active ingredients are old, and the core product has already experienced generic competition.

A new patent estate could be stronger if it covers a narrow, commercially important combination of:

• Preservative-free composition
• Defined particle-size distribution
• Specific rheological profile
• Sterile multidose package
• Metered delivery system
• Improved redispersion
• Reduced residual volume
• Validated manufacturing process

Such protection would still face design-around risk. The strongest commercial defense would combine patent rights with regulatory complexity, device integration, manufacturing know-how, and channel contracts.

Key Takeaways

• Ciprofloxacin/dexamethasone is a mature small-molecule otic combination with expired core exclusivity.
• The reference formulation uses hydroxyethyl cellulose, benzalkonium chloride, acetate salts, boric acid, sodium chloride, and sterile water.
• Preservative-free single-dose or multidose delivery is the clearest excipient-led opportunity.
• Improved redispersion, controlled viscosity, pediatric packaging, and metered delivery can support commercial differentiation.
• Generic competition is established, and price pressure makes an undifferentiated ANDA launch unattractive.
• The product has no biosimilar risk because it is a small-molecule combination.
• New patent value is most likely to come from formulation, device, packaging, particle engineering, and manufacturing claims.
• The best commercial strategy combines a regulatory-efficient formulation with a practical patient or caregiver benefit.

FAQs

Is ciprofloxacin/dexamethasone available as a preservative-free ear drop?

The reference Ciprodex formulation contains benzalkonium chloride. Preservative-free opportunities would require a new sterile packaging and contamination-control strategy, such as unit-dose packaging or a validated sterile multidose device.

Can ciprofloxacin/dexamethasone be reformulated as a clear solution?

A clear solution may be difficult because dexamethasone has limited aqueous solubility at the target concentration. A solution formulation would require a new solubilization system and extensive evaluation of tolerability, stability, potency, and local safety.

Does ciprofloxacin/dexamethasone have biosimilar competition?

No. Ciprofloxacin and dexamethasone are small molecules. Competition proceeds through generic drug applications rather than biosimilar applications.

What is the most valuable excipient in the formulation?

Hydroxyethyl cellulose is central because it controls suspension stability, viscosity, redispersion, and residence time. Its concentration and interaction with active particles can materially affect product performance.

Can a new ciprofloxacin/dexamethasone otic product receive patent protection?

Yes, but protection is more likely to cover a specific formulation, device, particle-size range, preservative-free system, packaging configuration, or manufacturing process than the active ingredients themselves.

References

1. U.S. Food and Drug Administration. (2003). Ciprodex prescribing information: Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension. FDA/DailyMed.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.

3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Generic drug development and approval standards. FDA.

4. U.S. Patent No. 5,980,882. (1999). Topical pharmaceutical compositions containing ciprofloxacin and dexamethasone. United States Patent and Trademark Office.

5. U.S. Food and Drug Administration. (2024). Inactive ingredient database. FDA.